Healthcare Providers and Services
Company Overview of Ranbaxy Pharmaceuticals, Inc.
Ranbaxy Pharmaceuticals, Inc. markets prescription and generic pharmaceutical products in the United States. Its product line includes anti-infective, cardiovascular, non-steroidal anti-inflammatory, anti-expectorant, analgesic, gastrointestinal, and central nervous system products, as well as controlled substances. The company was incorporated in 2004 and is based in Princeton, New Jersey. Ranbaxy Pharmaceuticals, Inc. is a subsidiary of Ranbaxy Inc.
600 College Road East
Princeton, NJ 08540
Founded in 2004
Key Executives for Ranbaxy Pharmaceuticals, Inc.
Head of Finance and Director
Chief Executive Officer of Ramnaxy and Managing Director of Ranbaxy
Vice President of Corporate Communications and Vice President of Government Affairs
Executive Director of Medical and Clinical Affairs
Senior Vice President, Regional Director of Americas and Director
Compensation as of Fiscal Year 2015.
Ranbaxy Pharmaceuticals, Inc. Key Developments
Cipher Pharmaceuticals Inc., Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. Enters into Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc
Oct 5 15
Cipher Pharmaceuticals Inc. along with its partners, Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. have entered into a settlement agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules). As part of the settlement agreement, Cipher, Ranbaxy and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica in the U.S. on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Attorney General Eric T. Schneiderman Announces Settlement with Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc for Entering into Anticompetitive Arrangement
Feb 19 14
Attorney General Eric T. Schneiderman announced a settlement with two generic pharmaceutical manufacturers, Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., resolving concerns that an agreement between them unlawfully restricted competition. The collusive agreement, under which each of the generic drug companies committed not to challenge certain regulatory exclusivities held by the other, served to protect each party's market positions with respect to dozens of drugs, and reduced the risk that each would face greater competition for its generic drugs. The settlement requires the companies to terminate their unlawful agreement, commit not to enter into similar agreements in the future, and make a monetary payment to the State. The case also represents the latest application of recent legal precedent arising out of challenges to pay for delay agreements between brand name and generic pharmaceutical manufacturers. The agreement between Ranbaxy and Teva relates to a type of regulatory exclusivity awarded to the first manufacturer that seeks to market a generic version of a brand manufacturer's drug prior to expiration of the brand manufacturer's patents.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|